These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 10630830

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Preserving target-organ function with candesartan cilexetil in patients with hypertension.
    Zannad F.
    Blood Press Suppl; 2000; 1():36-9. PubMed ID: 11059635
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 29. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
    Inada Y, Naka T.
    Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
    [Abstract] [Full Text] [Related]

  • 30. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF.
    J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
    [Abstract] [Full Text] [Related]

  • 31. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, Kiowski W, Marks DS, Alegria E, Dukát A, Lenz K, Arens HA.
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [Abstract] [Full Text] [Related]

  • 32. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, Rosei EA.
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
    [Abstract] [Full Text] [Related]

  • 35. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.
    Meredith PA.
    Curr Med Res Opin; 2007 Jul; 23(7):1693-705. PubMed ID: 17588300
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Differential clinical profile of candesartan compared to other angiotensin receptor blockers.
    Cernes R, Mashavi M, Zimlichman R.
    Vasc Health Risk Manag; 2011 Jul; 7():749-59. PubMed ID: 22241949
    [Abstract] [Full Text] [Related]

  • 39. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
    Asmar R, Lacourcière Y.
    J Hypertens; 2000 Nov; 18(11):1683-90. PubMed ID: 11081784
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
    Buter H, Navis GY, Woittiez AJ, de Zeeuw D, de Jong PE.
    Eur J Clin Pharmacol; 1999 Feb; 54(12):953-8. PubMed ID: 10192757
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.